By Pfizer | April 24, 2018Pfizer Doses First Patient Using Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
By Pfizer | April 23, 2018Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA (Meningococcal Group B Vaccine)
By Pfizer | April 10, 2018Update on Phase 3 Trial of Axitinib as Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
By Pfizer | April 4, 2018Agencies Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic NSCLC
By Pfizer | April 3, 2018Positive Topline Results From Phase 3 ATTR-ACT Study of Tafamidis in Patients With Transthyretin Cardiomyopathy
By Pfizer | February 15, 2018U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-generation ALK Inhibitor Lorlatinib
By Pfizer | February 6, 2018Phase III Trial Shows XTANDI (enzalutamide) Reduced Risk of Death by 71 Percent
By Pfizer | December 8, 2017Talazoparib Significantly Extends PFS in Phase III Embraca Trial of Patients with Metastatic Breast Cancer
By Pfizer | July 5, 2017Pfizer Initiates Phase 1 Clinical Trial to Evaluate Investigational GBS Vaccine
By Pfizer | May 11, 2017Sangamo Therapeutics, Pfizer Announce Collaboration for Hemophilia Gene A Therapy